



INDIANA UNIVERSITY

SCHOOL OF MEDICINE

Indiana CTSI 2020 Annual Meeting

Friday, September 11, 2020

Objectives

At the conclusion of this activity, participants should be able to:

- Discuss Imatinib as a Paradigm of Targeted Cancer Therapies.
- Describe how the use of circulating noninvasive biomarkers may allow for precision approaches targeting beta cell health in type 1 diabetes.
- Discuss the baseline transcriptional predictors of malaria outcomes.
- Describe development of an affordable and useful screening kit for the presence of dangerous lead
- Review recent discovery in triple negative breast cancer is revolutionizing cancer clinical trials
- Identify development of a long-acting and affordable opioid treatment

Accreditation Statement



JOINTLY ACCREDITED PROVIDER*
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Indiana University School of Medicine designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that IUSM may identify and resolve any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor. **Indiana University School of Medicine (IUSM) defines a **commercial interest** as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.*

There are no relevant financial relationships with a commercial interest for anyone who was in control of the content of this activity, except:

Brian Druker, MD disclosed he is a SAB member with Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program and Novartis. He also disclosed he is a SAB member and owns stocks with Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics and Third Coast Therapeutics. He serves on the board of directors and owns stock in Amgen. Dr. Druker also serves on the Board of Directors for Burroughs Wellcome Fund, CureOne and serves on the Joint Steering Committee for Beat AML LLS. He is the founder of VB Therapeutics and received research funding from Novartis, Bristol-Myers Squibb, Pfizer. He also has a sponsored Research Agreement with EnLiven Therapeutics. Dr. Druker disclosed he receives royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license and one Cytolmagine, Inc. exclusive license) All conflicts have been resolved.

The activity evaluation will be sent via email. Within 30-60 days following the activity, learners will receive a separate email with instructions on how to obtain proof of participation in this IUSM activity. For questions and concerns, please contact IU School of Medicine, Division of Continuing Medical Education, 317-274-0104, or cme@iu.edu.